[PDF] Top 20 Uma análise de eficiência do sector bancário português

... An Ovid Medline (1946 to September 2014) search was carried out using the terms “diabetes” and “dapagliflozin”. Papers and abstracts on animal studies and not in English were excluded, including any ... See full document

... American diabetes association; AHA: American heart association; BID: Twice daily; BMI: Body mass index; CI: Confidence intervals; CrI: Credible interval; DIC: Deviance information criteria; DPP-4: Dipeptidyl ... See full document

... Abstract: Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers plasma glucose by decreasing its renal ...of diabetes into a potential novel therapeutic ...secretion, ... See full document

... The MS clearly outlined the key aspects of the NMAs. It estimated fixed- and random-effects Bayesian hierarchical models using MCMC simulation in WinBUGS, evaluating the fit of the models through DIC. Prior distributions ... See full document

... From the 70’s, have been published data resolution for DM2 after bariatric surgery without being able to specify which was the mechanism of remission. Pories (1995), published data of resolution of DM2 in bariatric ... See full document

... of diabetes can be largely classified into macroangiopathy, eg, cardiovascular disease, stroke, and peripheral artery disease (PAD), and microangiopathy, eg, diabetic ...this review is to update physicians ... See full document

... insulin resistant (IR) (i.e., ß-cell dysfunction) is the crucial step in the development and progression of T2DM. In addition to ß-cell dysfunction, patients with T2DM have α-cell dysfunction, which manifests as ... See full document

... and diabetes. Importantly, ∼40% of patients with diabetes develop CKD, yet evidence from major multicenter randomized controlled trials shows that intensive blood glucose control through pharmacological ... See full document

... this review is to provide a review of current data of the most recently approved glucagon-like peptide (GLP)-1-receptor agonist, dulaglutide, in the treatment of type 2 ...the ... See full document

... this review, we sum- marize the previous findings regarding GLP-1 analogs and discuss the prospective clinical application of exenatide QW in the People’s Republic of ... See full document

... received dapagliflozin 5 mg once daily; if glycemic control was inadequate, the dose was increased to 10 mg once ...of dapagliflozin because this was an observational study; the timing and dosage were ... See full document

... bo-controlled study the authors explored whether the ad- dition of olanzapine versus placebo increased weight gain and improved psychological symptoms in 20 underweight female adolescents with AN-R type, who were ... See full document

... affect treatment outcomes. Atomoxetine is a nonstimulant treatment for ...the treatment of ADHD in patients with comorbid disorders, there is limited information about the impact of individual common ... See full document

... (35%). The p values for A Vs C and A Vs D were 0.01 and 0.002, respectively. This phase II trial study demonstrated a substantial clinical improvement in treating refractory RA with a short regimen of rituximab alone, or ... See full document

... type1 diabetic(T1DM) mice with betatrophin therapy at the same time it was found a notable increment in c-peptide of this group, the decline in the level of glucose in group that injected with betatrophin reflect the ... See full document

... in diabetes care from medication supply to cognitive services which aim to assist those with diabetes achieve the best possible clinical outcomes through supporting their ... See full document

... Male albino rats (100–120 g) were purchased from the National Research Centre (Cairo, Egypt). The animals were maintained in solid-bottom polycarbonate cages with stainless steel wire-bar lids and wooden dust-free litter ... See full document

... The literature search resulted in 7256 citations. Figure 1 presents the study flow mapping out the number of records identified, included and excluded and the reasons for their exclusion. After screening 230 ... See full document

... the treatment of type 2 diabetes, many of which are licensed, even for triple ...the diabetes therapy, ultimately leading to inadequate glucose ... See full document

... In this study, we have observed that there were few free mobile health applications “ apps ” related to the management of gami fi cation of type 1 diabetes in Google Play and App stores. In particular, only ... See full document